Merck reported solid second-quarter results, demonstrating strong operational performance and progress in its R&D pipeline with several upcoming filings. While management reaffirmed 2012 earnings guidance and expressed confidence in their strategy, they also highlighted challenges from the imminent SINGULAIR patent expiry, austerity measures in Europe, and currency headwinds. The balanced outlook suggests a neutral short-term impact on the stock price.

[0]